Lead Sponsor

BeiGene

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Histologically or cytologically confirmed locally advanced or metastatic solid tumors with a high prevalence of mucin-1 (MUC1) expression
•At least 1 measurable lesion per RECIST v1.1
•Stable Eastern Cooperative Oncology Group Performance Status of ≤ 1
•Adequate organ function
•Willing to use a highly effective method of birth control

•History of prior ≥ Grade 3 Cytokine Release Syndrome (CRS)
•History of severe Infusion-Related Reactions (IRRs), allergic reactions, or hypersensitivity to any ingredients or components of the study treatments
•Infection requiring systemic (oral or intravenous) therapy ≤ 14 days before the first dose of study drug(s), or participants with symptomatic COVID-19 infection
•Active leptomeningeal disease or uncontrolled, untreated brain metastasis
•Active autoimmune disease or history of autoimmune disease(s) that may relapse